Keyphrases
Conference Report
100%
Treatment Recommendations
100%
Consensus Conference
100%
Follicular Lymphoma
100%
Radioimmunotherapy
100%
Treatment Algorithm
18%
Chemoimmunotherapy
18%
Chemotherapy
9%
Healthcare Professionals
9%
Treatment Options
9%
Disease Control
9%
Oncologists
9%
Hematologist
9%
Overall Response Rate
9%
Treatment Decisions
9%
Patient Benefit
9%
Study Support
9%
Response Rate
9%
Antibody Targeting
9%
Clinical Effect
9%
Safety Profile
9%
Radionuclides
9%
Patient Selection
9%
Rituximab
9%
Myelosuppression
9%
Time to Progression
9%
Induction Therapy
9%
Relapsed or Refractory
9%
Secondary Malignancy
9%
Complete Response
9%
Lymphoma Therapy
9%
Induction Chemotherapy
9%
CD20
9%
Consensus Recommendations
9%
Subsequent Therapy
9%
Tositumomab
9%
90Y-ibritumomab Tiuxetan
9%
B-cell non-Hodgkin Lymphoma (B-NHL)
9%
Efficacy Profile
9%
Medicine and Dentistry
Follicular Lymphoma
100%
Radioimmunotherapy
100%
Chemoimmunotherapy
18%
Diseases
18%
Radioisotope
9%
Rituximab
9%
CD20
9%
Non-Hodgkin Lymphoma
9%
Yttrium 90
9%
Bone Marrow Suppression
9%
Iodine 131
9%
B Cell
9%
Clinical Study
9%
Tositumomab
9%
Cancer
9%
Oncologist
9%
Immunotherapy
9%
Induction Chemotherapy
9%
Ibritumomab Tiuxetan
9%